Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||uveal melanoma||not applicable||Sotrastaurin||Phase I||Actionable||In a Phase I trial, AEB071 treatment was safe and tolerable in patients with uveal melanoma and led to a partial response in 3% (4/153), stable disease in 50% (76/153) with a median duration of 15 weeks, and a median progression-free survival of 3.5 months (PMID: 32029634; NCT01430416).||32029634|